The hepatitis C virus (HCV) is very successful in establishing persistent
infections by evading the immune system and predominantly infecting
hepatocytes. HCV was known as non-A non-B hepatitis since the 1970’s and
identified as a unique virus in 1989 1. HCV is a single-strand positive
sense RNA virus belonging to the Flaviviridae family, has six major
genotypes (1 to 6) and more than 100 subtypes have been identified. The
single ~9600 nucleotide RNA molecule carries one open reading frame
encoding for the structural proteins core, envelope 1 (E1), envelope 2
(E2), p7, and 6 non-structural proteins (NS) needed for replication
(NS2, NS3, NS4a, NS4b, NS5a and NS5b). The current model of HCV
infection suggests that after entering circulation, HCV is transported
to the liver via lipoproteins where HCV binds to low density lipoprotein
receptors, and possibly DC-sign and other receptors on hepatocytes,
followed by viral entry in a clathrin-dependent endocytic process
requiring interaction between the viral envelope with cell surface
tetraspanin CD81, scavenger receptor type B class I, and the tight
junction proteins claudin-1 and occludin (reviewed in 2).
Controversy exists whether HCV directly impairs immune cell functions by
infecting these cells. However, following infection, innate immunity
and the HCV-specific immune response mediated via T cells are
functionally impaired, and unable to eliminate the HCV in the majority
of individuals 3-6. Only a minority of infected patients are able to
clear HCV spontaneously, and about 80% develop a chronic infection with
viral replication primarily occurring in the liver 7.
It is estimated that globally 120 to 170 million patients are
persistently infected with HCV.
http://repub.eur.nl/res/pub/30639/111207_Claassen%2C%20Mark%20Arthur%20Alvin_Bewerkt.pdf
http://repub.eur.nl/res/pub/30639/111207_Claassen%2C%20Mark%20Arthur%20Alvin_Bewerkt.pdf
No comments:
Post a Comment